7.04

1.12% -0.08

After Hours: 7.04

Fennec Pharmaceuticals Inc (FENC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Fennec Pharmaceuticals Inc stock is currently priced at $7.04, with a 24-hour trading volume of 306.01K. It has seen a -1.12% decreased in the last 24 hours and a -27.42% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.99 pivot point. If it approaches the $7.32 resistance level, significant changes may occur.

Previous Close:

$7.12

Open:

$7.03

24h Volume:

306.01K

Market Cap:

$192.35M

Revenue:

$21.25M

Net Income/Loss:

$-16.05M

P/E Ratio:

-7.04

EPS:

-1

Net Cash Flow:

$-17.14M

1W Performance:

-27.79%

1M Performance:

-27.42%

6M Performance:

-15.38%

1Y Performance:

-6.63%

1D Range:

$6.70

$7.09

52W Range:

$6.30

$11.92

Fennec Pharmaceuticals Inc Stock (FENC) Company Profile

Name

Fennec Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

919-636-4530

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC

Employee

Twitter

@FennecPharma

Next Earnings Date

2024-06-11

Latest SEC Filings

FENC's Discussions on Twitter

Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-07-22	Initiated	CapitalOne	Overweight
Aug-08-22	Resumed	Craig Hallum	Buy
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight
Oct-11-18	Initiated	Goldman	Buy

Fennec Pharmaceuticals Inc Stock (FENC) Latest News

Fennec Pharmaceuticals Inc Forecasted to Earn FY2024 Earnings of ($0.09) Per Share (NASDAQ:FENC) - Defense World

Defense World

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Expected to Earn Q2 2024 Earnings of ($0.14) Per Share - Defense World

Defense World

Q2 2024 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Lifted by Analyst - Defense World

Defense World

FY2024 EPS Estimates for Fennec Pharmaceuticals Inc. Decreased by Analyst (TSE:FRX) - MarketBeat

MarketBeat

HC Wainwright Equities Analysts Boost Earnings Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX) - Defense World

Defense World

Analysts Issue Forecasts for Fennec Pharmaceuticals Inc.'s Q2 2024 Earnings (TSE:FRX) - Defense World

Defense World

Fennec Pharmaceuticals Inc Stock (FENC) Financials Data

Fennec Pharmaceuticals Inc (FENC) Revenue 2024

FENC reported a revenue (TTM) of $21.25 million for the quarter ending December 31, 2023.

Fennec Pharmaceuticals Inc (FENC) Net Income 2024

FENC net income (TTM) was -$16.05 million for the quarter ending December 31, 2023, a +32.34% increase year-over-year.

Fennec Pharmaceuticals Inc (FENC) Cash Flow 2024

FENC recorded a free cash flow (TTM) of -$17.14 million for the quarter ending December 31, 2023, a +5.07% increase year-over-year.

Fennec Pharmaceuticals Inc (FENC) Earnings per Share 2024

FENC earnings per share (TTM) was -$0.61 for the quarter ending December 31, 2023, a +31.46% growth year-over-year.

Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 22 '24	Option Exercise	2.31	22,223	51,335	22,223
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 22 '24	Sale	9.32	22,223	207,029	0
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 19 '24	Option Exercise	2.31	22,222	51,333	22,222
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 19 '24	Sale	9.34	22,222	207,442	0
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 18 '24	Sale	9.62	22,222	213,776	0
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 17 '24	Sale	9.91	22,222	220,220	22,222
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 16 '24	Sale	10.28	22,222	228,389	0
RALLIS CHRIS A	Director	Apr 15 '24	Option Exercise	10.45	1,389	14,515	45,838
Haigh Adrian	CHIEF OPERATING OFFICER	Apr 15 '24	Sale	10.30	22,222	228,793	22,222
RALLIS CHRIS A	Director	Apr 15 '24	Sale	10.45	800	8,360	44,449

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.